• Featured Product
  • KD/KO Validated

FAT10 Polyclonal antibody

FAT10 Polyclonal Antibody for WB, IHC, ELISA

Host / Isotype

Rabbit / IgG


human and More (2)





Cat no : 13003-2-AP


Diubiquitin, FAT10, GABBR1, UBD, UBD 3, ubiquitin D, Ubiquitin like protein FAT10

Tested Applications

Positive WB detected inTNF alpha and IFN gamma treated HepG2 cells
Positive IHC detected inhuman tonsillitis tissue, human lung cancer tissue, human lymphoma tissue, human stomach cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:500-1:2000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

13003-2-AP targets FAT10 in WB, IF, IHC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen FAT10 fusion protein Ag3680
Full Name ubiquitin D
Calculated Molecular Weight 165 aa, 18 kDa
Observed Molecular Weight20 kDa, 70kDa
GenBank Accession NumberBC012472
Gene Symbol UBD
Gene ID (NCBI) 10537
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

FAT10, also named UBD, contains two ubiquitin-like domains. It is a ubiquitin-like protein modifier that can be covalently attached to the target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner. FAT10 also has important roles in cell mitosis, chromosome instability, apoptosis, and immune response. FAT10 mediates apoptosis in a caspase-dependent manner, especially in the renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN). It promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). FAT10 regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. It may be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. FAT10 may be a marker for precancerous lesions and may promote cancer progression. This antibody is a rabbit polyclonal antibody raised against full-length FAT10 of human origin.


Product Specific Protocols
WB protocol for FAT10 antibody 13003-2-APDownload protocol
IHC protocol for FAT10 antibody 13003-2-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Cancer Res

The Ubiquitin-like Protein FAT10 Stabilizes eEF1A1 Expression to Promote Tumor Proliferation in a Complex Manner.

Authors - Xiuxia Liu
  • KD Validated

J Biol Chem

Ubiquitin D regulates IRE1α/JNK-dependent apoptosis in pancreatic beta cells.

Authors - Flora Brozzi


Identification of novel genes selectively expressed in the follicle-associated epithelium from the meta-analysis of transcriptomics data from multiple mouse cell and tissue populations.

Authors - Kobayashi Atsushi A

Toxicol Lett

Ochratoxin A induces karyomegaly and cell cycle aberrations in renal tubular cells without relation to induction of oxidative stress responses in rats.

Authors - Taniai Eriko E


c-Rel is dispensable for the differentiation and functional maturation of M cells in the follicle-associated epithelium.

Authors - Anuj Sehgal

J Appl Toxicol

Onset of hepatocarcinogen-specific cell proliferation and cell cycle aberration during the early stage of repeated hepatocarcinogen administration in rats.

Authors - Masayuki Kimura